Marco Troiani was the laboratory manager of DB Labs from its founding 2015-2016. His responsibilities included developing methods for the detection of terpenes and solvents (GC-MS), metals (ICP-MS), pesticides (GC-MS-MS), and Total Yeast and Mold, Total Aerobic Bacteria, Total Coliform Bacteria, and Salmonella spp. in cannabis and associated products, as well as hiring, training and managing lab employees. Additionally, Mr. Troiani was responsible for writing and maintaining the laboratory QAQC manual, and was responsible for personally signing each certificate of analysis released to a client. Mr. Troiani worked with representatives from the state of Maine to consult regarding the legalization of cannabis in that jurisdiction. Mr.
Troiani’s previous experience includes working as a lab technician at Steep Hill under Mr.Sguera, and previously working at the Lokey Research Group in Santa Cruz, CA on synthesizing and assaying for membrane permeability a series of novel peptides derived from natural venoms. Mr Troiani’s work with analytical laboratories includes: developing new methods, validating existing methods, increasing the robustness of quality and client data generated by a laboratory, often to meet accreditation standards. Mr. Troiani’s work with extraction laboratories includes: increasing yields, purity and terpene retention of cannabis concentrates. Work with medical laboratories includes: presenting data generated by peer-reviewed publications on the safety and efficacy of cannabis as a medicine, educating doctors and clinicians on the chemical composition of cannabis, education on analysis performed on cannabis for potency and safety standards, education on the endocannabinoid system and the properties of cannabinoids in the human body. Mr. Troiani has lectured on the science of cannabis in various contexts: American Chemical Society Fall 2016, Pesticide
extraction and detection in cannabis; CannMed Conference 2017, Medical benefits of terpenes in cannabis; American Chemical Society Fall 2017, Terpenes in cannabis and statistical variation between strains.
Savino Sguera was the Laboratory Director of Steep Hill Lab from 2011 – 2013 and DB Labs from 2014–2016. His duties included: development and validation of new analytical methods for LC-MS, GC-MS, NIR Spectroscopy, and Mold Plating; sample preparation and data analysis; client reporting; drafting Standard Operating Procedures and other requirements for ISO certification; hiring and training of new laboratory personnel; client consultations. He worked with representatives from the Washington State Liquor Control Board to draft state legislation regarding cannabis quality control. His tasks included extensive scientific journal research, report generation, and meeting with state representatives and outside consulting agencies. The specific content of the legislation includes: chromatographic method specification and validations; identification of important cannabinoids and terpenes; identification of all possible chemical contaminants including pesticides, herbicides, solvents, heavy metals, etc; determining acceptable exposure limits of stated contaminants; and other quality control aspects of laboratory requirements. Since 2015, Savino has served as a member of the Independent Laboratory Advisory Committee for the State of Nevada Department of Public and Behavioral Health. Since 2011, Savino Sguera has been active in the Medical Marijuana community in the San Francisco Bay Area. He has given lectures on cannabinoid biochemistry and pharmacodynamics, including at The American Chemical Society Fall 2016 and Fall 2017 meetings and CannMed 2017; he has participated in radio panels discussing the medical efficacies of cannabis in treatment of various conditions; he has personally consulted with patients, caregivers, producers, and the general public to clarify and explain the most recent scientific developments and discuss possible treatment options with proper MD referrals.
As cannabis sales expand worldwide, there is an immediate demand for accurate taxonomy and labeling of products. Many studies have shown common cultivar names to be insufficient in describing both the chemical profile of a given product and genetic lineage of the plant. Digamma presents the DiscOmic System as a solution to these issues, providing a visual label accessible to end-users and product developers alike, utilizing high-quality data and the latest AI methodology. Incorporating genetic, cultivation, and patient data with this system, Project Cannabinome seeks an understanding of cannabis enzymology and pharmacology that surpasses that of other plant medicines to date, and sets a framework for studying others in the future.